

Claim 1, lines 2-3 from the bottom, delete ";for the production of drugs".

REMARKS

Claim 1 is pending in this application.

The examiner is again requested to reconsider the requirement for election/restriction. Where, as in the instant case, the compounds share a common technical feature, the nature of the substituents does not justify a holding of lack of unity of invention. See Examples 4, 18, 19 and 20 of the PCT Administrative Instructions, M.P.E.P., AI-49, Rev. 1, Sept. 1995.

Entry is requested of the revised Abstract of the Disclosure which is submitted herewith.

The examiner is requested to favorably reconsider the rejection of claim 1 under 35 USC 112, second paragraph as being indefinite in view of the foregoing amendment. It is now clear that the claim is directed to a method of treating. Favorable reconsideration is solicited.

In view of the foregoing amendment and remarks, the applicants respectfully urge that the sole claim is now allowable, and allowance of the claim is solicited.

Please charge any shortage in fees due in connection with the filing of this paper, including Extension of Time fees to Deposit Account No. 11.0345. Please credit any excess fees to such deposit account.

Respectfully submitted,

KEIL & WEINKAUF


Henry R. Jones
Reg. No. 32,677

1101 Connecticut Avenue, N.W.
Washington, D.C. 20036
(202) 659-0100

HRJ/kas